Prognostic Value of the HALP Index, Erythrocyte Sedimentation Rate, and Rheumatoid Factor in Rheumatoid Arthritis: A Laboratory-Based Multivariate Analysis

Prediction model of RA

  • Xiaohua Xu Departments of Clinical Laboratory, Longyan First Affiliated Hospital of Fujian Medical University
  • Xiaohua Huang Departments of Clinical Laboratory, Longyan First Affiliated Hospital of Fujian Medical University
  • Yongfang Lu Departments of Clinical Laboratory, Longyan First Affiliated Hospital of Fujian Medical University
  • Defei Zeng Department of Reproductive Medicine, Longyan First Affiliated Hospital of Fujian Medical University
DOI: https://doi.org/10.5937/jomb0-61610
Keywords: rheumatoid arthritis, HALP index, erythrocyte sedimentation rate, rheumatoid factor, biochemical markers, laboratory medicine

Abstract


Background: Biochemical and hematological indices play a critical role in evaluating systemic inflammation and disease activity in rheumatoid arthritis (RA). This study investigated the prognostic value of the hemoglobin–albumin–lymphocyte–platelet (HALP) index, in combination with erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF), for predicting RA disease progression.

Methods: A retrospective analysis was performed on 146 RA patients admitted between December 2022 and December 2023. Laboratory variables included HALP index, ESR, RF, C-reactive protein, anti-CCP antibodies, hemoglobin, albumin, lymphocyte and platelet counts, and serum creatinine. Measurements were obtained using standardized automated hematology and biochemical analyzers. Disease activity and radiographic joint damage scores were also assessed. Statistical approaches included correlation analysis, regression analysis, and receiver operating characteristic (ROC) curve evaluation.

Results: The HALP index, ESR, and RF were significantly associated with RA disease progression. The HALP index demonstrated a strong correlation with disease activity (r=0.602, P<0.001). ROC analysis showed an area under the curve (AUC) of 0.858 for HALP, 0.841 for ESR, and 0.924 for RF. When combined in a multivariate regression model, the predictive performance improved (AUC=0.943).

Conclusion: The HALP index, as a composite biochemical marker, in combination with ESR and RF, provides significant prognostic information for RA progression. These findings underscore the importance of laboratory-based indices in refining prognostic assessments and highlight their potential role in personalized disease management.

References

1. Diaz-Gonzalez F, Hernandez-Hernandez MV. Rheumatoid arthritis. Med Clin-Barcelona 2023; 161(12): 533-42.
2. Falahee M, Raza K. Rheumatoid arthritis prevention: any takers? Rmd Open 2021; 7(1):
3. Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Front Immunol 2021; 12(686155.
4. Malhotra H, Garg V, Singh G. Biomarker Approach Towards Rheumatoid Arthritis Treatment. Curr Rheumatol Rev 2021; 17(2): 162-75.
5. Jang S, Kwon E, Lee JJ. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci 2022; 23(2):
6. Sparks JA. Rheumatoid Arthritis. Ann Intern Med 2019; 170(1): ITC1-16.
7. Smith MH, Berman JR. What Is Rheumatoid Arthritis? Jama-J Am Med Assoc 2022; 327(12): 1194.
8. Cush JJ. Rheumatoid Arthritis: Early Diagnosis and Treatment. Med Clin N Am 2021; 105(2): 355-65.
9. Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic Manifestations of Rheumatoid Arthritis. Clin Chest Med 2019; 40(3): 545-60.
10. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev 2021; 20(4): 102776.
11. Daikh DI. Rheumatoid arthritis: Evolving recognition of a common disease. Best Pract Res Cl Rh 2022; 36(1): 101740.
12. Giannini D, Antonucci M, Petrelli F, Bilia S, Alunno A, Puxeddu I. One year in review 2020: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 2020; 38(3): 387-97.
13. Cush JJ. Rheumatoid Arthritis: Early Diagnosis and Treatment. Rheum Dis Clin N Am 2022; 48(2): 537-47.
14. Gravallese EM, Firestein GS. Rheumatoid Arthritis - Common Origins, Divergent Mechanisms. New Engl J Med 2023; 388(6): 529-42.
15. Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev 2021; 30(160):
16. Hugon J. Rheumatoid arthritis and cognitive decline. Joint Bone Spine 2022; 89(3): 105346.
17. Han H, Hu S, Du J. Predictive value of the hemoglobin-albumin-lymphocyte-platelet (HALP) index for ICU mortality in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Intern Emerg Med 2023; 18(1): 85-96.
18. Calderillo Ruiz G, Lopez Basave H, Vazquez Renteria RS, Castillo Morales A, Guijosa A, Castillo Morales C, et al. The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population. J Oncol 2022; 2022: 4324635.
19. van Sleen Y, van der Geest KSM, Huckriede ALW, van Baarle D, Brouwer E. Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol 2023; 19(9): 560-75.
20. Leetanaporn K, Hanprasertpong J. Predictive Value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Index on the Oncological Outcomes of Locally Advanced Cervical Cancer Patients. Cancer Manag Res 2022; 14: 1961-72.
21. Khavanin Zadeh M, Omrani Z, Cheraghali R, Hashemaghaee M. ESR, CRP, and failure of Arterio-Venous Fistula (AVF). Med J Islam Repub Iran 2021; 35: 125.
22. Rech AB, Kinoshita A, Donate PM, Baffa O. ESR dosimetry with lithium, potassium, and sodium compounds. Appl Radiat Isotopes 2022; 181: 110105.
23. Kishkun AA, Siniak MY. Standardization of methods for determining ESR. Klin Lab Diagn 2021; 66(5): 271-8.
24. Georas SN, Donohue P, Connolly M, Wechsler ME. JAK inhibitors for asthma. J Allergy Clin Immun 2021; 148(4): 953-63.
25. Mukhtar M, Sheikh N, Batool A, Saleem T, Khawar MB, Irfan M, et al. TLR-8, TNF-alpha, and ESR-1alpha Gene Polymorphism Susceptibility in Onset of Arthritis. Genet Res 2022; 2022: 9208765.
Published
2025/11/05
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Xiaohua Xu, Xiaohua Huang, Yongfang Lu, Defei Zeng

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.